Cargando…
Clobazam and Its Active Metabolite N-desmethylclobazam Display Significantly Greater Affinities for α(2)- versus α(1)-GABA(A)–Receptor Complexes
Clobazam (CLB), a 1,5-benzodiazepine (BZD), was FDA-approved in October 2011 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older. BZDs exert various CNS effects through allosteric modulation of GABA(A) receptors. The structurally disti...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922815/ https://www.ncbi.nlm.nih.gov/pubmed/24533090 http://dx.doi.org/10.1371/journal.pone.0088456 |